Archives for 

Biologics Litigation

Amgen v. Sandoz Appeal: Parties Submit Supplemental Briefing; Court Grants US Extension to File Amicus Brief

Amgen v. Sandoz (filgrastim)  •  Biologics Litigation  •  Biosimilar News  •  BPCIA and Related U.S. Statutes  •  U.S. Biosimilar Litigation News
As we previously reported, following the Supreme Court’s June 12, 2017 decision in Sandoz v. Amgen,  the Federal Circuit on July 26, 2017, issued an order recalling its October 23, […]

View More

Janssen v. Celltrion: CAFC & District Court Litigation Update

Biologics Litigation  •  Biosimilar News  •  Janssen v. Celltrion (infliximab)  •  U.S. Biosimilar Litigation News
As we previously reported last year, in the ongoing Janssen v. Celltrion litigation concerning Celltrion’s Inflectra®, a biosimilar of Janssen’s Remicade® (infliximab), Janssen appealed the district court’s partial final judgment of invalidity of Janssen’s ’471 patent based on […]

View More

Amgen v. Sandoz: Federal Circuit Vacates Opinion and Mandate, Reinstates Appeal, Orders Further Briefing on Remanded Issues

Amgen v. Sandoz (filgrastim)  •  Approved Biosimilar Products  •  Biologics Litigation  •  Biosimilar News  •  BPCIA and Related U.S. Statutes  •  U.S. Biosimilar Litigation News  •  U.S. Federal Circuit Decisions  •  U.S. Supreme Court Decisions
As we previously reported, following the Supreme Court’s decision in Sandoz v. Amgen, Sandoz requested a remand to the District Court to answer the two questions that the […]

View More